MORGAN STANLEY - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$14,412,224
+208.3%
523,700
+280.1%
0.00%
Q2 2023$4,675,011
-73.6%
137,784
-72.1%
0.00%
-100.0%
Q1 2023$17,739,760
+95.4%
493,045
+142.1%
0.00%
+100.0%
Q4 2022$9,078,417
+58.7%
203,689
+0.2%
0.00%0.0%
Q3 2022$5,719,000
-56.0%
203,383
-57.8%
0.00%
-50.0%
Q2 2022$12,995,000
-62.6%
482,027
-52.7%
0.00%
-60.0%
Q1 2022$34,708,000
+193.6%
1,019,024
+233.1%
0.01%
+400.0%
Q4 2021$11,821,000
+23.3%
305,933
+72.3%
0.00%0.0%
Q3 2021$9,584,000
+132.7%
177,536
+44.2%
0.00%0.0%
Q2 2021$4,118,000
+809.1%
123,159
+459.7%
0.00%
Q1 2021$453,000
+32.1%
22,005
+12.6%
0.00%
Q4 2020$343,000
+45.3%
19,546
+23.1%
0.00%
Q3 2020$236,000
-21.6%
15,879
-31.4%
0.00%
Q2 2020$301,000
+812.1%
23,142
+18.7%
0.00%
Q1 2020$33,000
-31.2%
19,503
-7.9%
0.00%
Q4 2019$48,000
+140.0%
21,170
+124.1%
0.00%
Q3 2019$20,000
-33.3%
9,446
-15.1%
0.00%
Q2 2019$30,000
+172.7%
11,132
+372.1%
0.00%
Q1 2019$11,0002,3580.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders